America's Weapons, Made in Germany: Who the Licensing Boom Actually Pays

Germany is about to build some of America's most prized weapons on its own soil, and the deal reads like a threat to the U.S. defense giants that have thrived on government paychecks for decades. Borrowed missile designs, handed to a European rival — surely that trims the growth of Lockheed Martin and RTX?

Read the economics instead, and it points the other way. What looks like America giving away its crown jewels is really a capacity-sharing agreement inside a rearmament boom that has no end date in sight. The open question isn't whether the U.S. defense dividend payers survive it. It's who captures the volume, and what the income investor is actually being paid for on each side of the Atlantic.

What Berlin is actually asking for

German Defense Minister Pistorius is in Washington this week for talks with U.S. Defense Secretary Pete Hegseth on expanding Germany-U.S. defense-industrial cooperation, following months of groundwork. The essence, as Pistorius framed it in July: Germany lacks certain capabilities, or cannot produce them fast enough, so it wants to build select U.S. weapons — or at least components — under license at home. This is explicitly framed as a way to make NATO "more European" and cut "one-sided transatlantic dependencies," all without breaking the link to Washington.

The scope is concrete. At the NATO summit in Ankara in July, Lockheed Martin and Germany's Rheinmetall signed a memorandum of understanding toward a joint venture to produce ATACMS missiles in Europe — the first time those weapons would be made outside the United States. Germany, the Netherlands, Poland and Sweden separately committed to exploring a PAC-3 missile maintenance facility in Europe. On the RTX side, Raytheon has a $3.7 billion contract to supply Patriot GEM-T interceptors and plans a new production line in Schrobenhausen, Germany. Tomahawk cruise missiles are on the table too.

The money follows the bottleneck, not the blueprint

Here is the part the headline hides. A weapons program's value does not live in the drawing; it lives in the factory that can actually turn out the missile, and in the government willing to pay for it. The U.S. plants that build ATACMS and Patriots are the bottleneck — they cannot make enough, fast enough, for a Europe that spent 14% more on defense in 2025 alone while punching toward 3.5% of GDP by 2029.

Licensing moves the bottlenecks onto other people's balance sheets. European partners buy the factory floor, the labor, and a large share of the public money, while the U.S. primes collect licensing and joint-venture economics and keep their intellectual property. Washington's incentive is not charity; it is staying strategically irreplaceable inside Europe's defense base rather than watching the continent buy main-force European (or worse, offshore) systems. That is the real toll being collected — not the next quarter's export revenue.

The volume lands on the European side. Rheinmetall is the emblematic winner: first-half 2026 sales up 39% to €5.2 billion, a record €63.8 billion order backlog, and management guiding 2026 revenue up to €14.2 billion. That is a genuine compounding machine — and yet Rheinmetall shares are down roughly 15% this year, because the market is weighing whether the growth is already paid for.

The dividend arithmetic on both sides

This is where the income investor's lens sharpens the picture. Rheinmetall is the growth story of the licensing boom, but it is not an income story: it pays a token dividend, and its valuation has run far ahead of the payout it can fund. If your goal is a stream that compounds through a full cycle, Rheinmetall fails the first test before you get to the balance sheet.

The U.S. primes clear the bar easily. Lockheed yields about 2.6% with 22 straight years of dividend increases, a payout near 65% of trailing earnings, and roughly $8.7 billion of trailing free cash flow. RTX yields a thinner 1.4% but has raised for 23 consecutive years, pays out only about half of earnings, and generated close to $11 billion of free cash flow. Both structures have room in the payout one, two, or three full cycles out, regardless of whether a given missile is assembled in Camden, Arkansas, or Schrobenhausen, Germany. Licensing reallocates where the revenue is booked; it does not knock a hole in the cash feeding the dividend.

The valuation discipline still matters. Lockheed trades around 19 times trailing earnings — a defensible price for a toll-like business with the payout profile above. RTX at roughly 34 times is a growth valuation; the license headline is not a reason to pay that multiple. And the honest risk to name: every license exported is a bit of U.S. manufacturing exclusivity surrendered, and a bit less leverage in future export negotiations. That is a slow, soft erosion of margin leverage, not a threat to dividend durability.

Where that leaves a conviction

The instinct to read this headline as a strike against Lockheed and RTX is understandable and wrong. What the talks in Washington this week may be paving the way for is a toll being widened — a rearmament pipeline that funds itself with public money on both continents, with the U.S. primes monetizing their designs and the European producers building the volume. For a focused, income-first portfolio, the durable exposure remains the American dividend growers whose balance sheets and payout ratios can carry the compounding. The licensing boom — and Rheinmetall's surge with it — is the growth trade for whoever can stomach its valuation, not the way an income portfolio should spend its concentration.